Kezar Life Sciences, Inc. (KZR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is Christopher J. Kirk.
KZR has IPO date of 2018-06-21, 55 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $54.25M.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
